Form 8-K TG THERAPEUTICS, INC. For: May 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
TG Therapeutics (TGTX) PT Raised to $40 at Ladenburg Thalmann
May 2, 2024 6:34 AM EDTLadenburg Thalmann analyst Matthew Kaplan raised the price target on TG Therapeutics (NASDAQ: TGTX) to $40.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "Strong BRIUMVI 1Q24 revenues with >25% Q/Q growth; TGTX increased BRIUMVI 2024 revenue guidance to $270-$290 million from $220-$260 million. TG... More
